Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Liquid Biopsy – Using the Right Tool for the Right Job

Liquid biopsy has captured the imagination of investors and the mainstream press alike.  While the ability to assess patients non-invasively is appealing to physicians and patients, there remains much confusion regarding the capabilities and limitations of various technologies.  This session will provide meaningful data and debate on the clinical utility of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes.  Companies representing each technology will present and answer audience questions regarding what some estimates forecast to be a $10BN diagnostic industry.


Murali Prahalad, Ph.D., President & CEO, Epic Sciences

Dr. Prahalad currently holds the title of President and CEO of Epic Sciences, Inc. (EPIC), a venture backed cancer management company specializing in the detection and analysis of circulating tumor cells (CTCs). Read Full Bio

Helmy Eltoukhy, Ph.D., CEO, Guardant Health

Helmy Eltoukhy, PhD, is a biotech pioneer with deep expertise in next-generation digital sequencing technologies and genetic analysis systems. He is currently the co-founder and CEO of Guardant Health, the market leader in liquid biopsies. Helmy’s prior startup, Avantome, was a leader in low-cost sequencing, before being acquired by Illumina. Read Full Bio

Mark Erlander, Ph.D., CSO, Trovagene

Dr. David Berz is triple Board Certified in Internal Medicine, Hematology and Oncology. Dr. Berz has many years of extensive experience in the field of oncology, including private practice and clinical research, and is currently a scientist at City of Hope. Dr. Berz Specializes in thoracic/lung malignancies, melanoma, and cancer immune-therapy. Read Full Bio

Phil Stephens, Ph.D., Chief Scientific Officer Foundation Medicine

Dr. Stephens joined Foundation Medicine in March 2011, bringing more than a decade of experience in cancer genomics to the company. Dr. Stephens is a world-renowned expert in next-generation sequencing and cancer genome analysis and has authored numerous publications in Nature, Nature Genetics, Nature Medicine, Cell and other high-profile journals. Read Full Bio

Jean-Francois Laes, Ph.D., CTO, Oncodna

Jean-François did his PhD in cancer genetics at ULB (Université Libre de Bruxelles) and then worked at the Jules Bordet Institute where he set up an Affymetrix microarray platform for use in translational research and clinical studies. Read Full Bio

Web Analytics